Page last updated: 2024-08-23

thymopentin and Disease Exacerbation

thymopentin has been researched along with Disease Exacerbation in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beall, G; Blick, G; Calabrese, LH; Conant, MA; Fisher, A; Galpin, JE; Goldstein, G; Grossman, HA; Hirsch, RL; Stampone, P	1
Fisher, AC; Goldstein, G; Hirsch, RL; Merigan, TC; Meyerson, LA; Winters, MA	1

Trials

2 trial(s) available for thymopentin and Disease Exacerbation

Article	Year
Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial. Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1995, Mar-01, Volume: 8, Issue:3 Topics: Adult; CD4 Lymphocyte Count; Disease Progression; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Follow-Up Studies; HIV; HIV Core Protein p24; HIV Infections; Humans; Injections, Subcutaneous; Male; Middle Aged; Patient Compliance; Pentamidine; Pneumonia, Pneumocystis; Prognosis; Proportional Hazards Models; Thymopentin; Trimethoprim, Sulfamethoxazole Drug Combination; Zidovudine	1995
The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin. AIDS (London, England), 1996, Volume: 10, Issue:2 Topics: Adjuvants, Immunologic; Adult; Antigen-Antibody Complex; Antiviral Agents; CD4 Lymphocyte Count; Disease Progression; Double-Blind Method; Female; HIV Core Protein p24; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation; Predictive Value of Tests; Prognosis; Retrospective Studies; RNA, Viral; Thymopentin; Viral Load; Zidovudine	1996

Article

Year

Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial.

Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1995, Mar-01, Volume: 8, Issue:3

Topics: Adult; CD4 Lymphocyte Count; Disease Progression; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Follow-Up Studies; HIV; HIV Core Protein p24; HIV Infections; Humans; Injections, Subcutaneous; Male; Middle Aged; Patient Compliance; Pentamidine; Pneumonia, Pneumocystis; Prognosis; Proportional Hazards Models; Thymopentin; Trimethoprim, Sulfamethoxazole Drug Combination; Zidovudine

1995

The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin.

AIDS (London, England), 1996, Volume: 10, Issue:2

Topics: Adjuvants, Immunologic; Adult; Antigen-Antibody Complex; Antiviral Agents; CD4 Lymphocyte Count; Disease Progression; Double-Blind Method; Female; HIV Core Protein p24; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation; Predictive Value of Tests; Prognosis; Retrospective Studies; RNA, Viral; Thymopentin; Viral Load; Zidovudine

1996